National Toxicology Program

National Toxicology Program
http://ntp.niehs.nih.gov/go/295

AIDS Therapeutics Toxicity Studies Program

Infection with human immunodeficiency virus (HIV) causes immunosuppression and leads to acquired immunodeficiency syndrome (AIDS) with a broad spectrum of opportunistic infections. Prophylaxis and treatment of AIDS are generally combination therapies of antiretroviral agents with antimicrobial drugs specific for the opportunistic infections. The National Institute of Environmental Health Sciences (NIEHS), under the AIDS research program, collaborates with other institutes of the NIH, other government agencies, and pharmaceutical companies to evaluate the reproductive/developmental toxicity, general toxicity, immunotoxicity and neurotoxicity of AIDS therapeutics. These evaluations may include single therapeutic agents or combination therapies when the toxic potential of these agents in animal models is not available or is incomplete. The studies with combination therapies are very important in that they will increase awareness and understanding of interactions between antiretroviral therapies and other drugs/substances that HIV-infected individuals may be using.

NIEHS AIDS Therapeutics Toxicity Reports:

  • AIDS Toxicity Report Number 1: NIEHS Technical Report on the Reproductive, Developmental, and General Toxicity Studies of Pyrazinamide (CAS No. 98-96-4) Administered by Gavage to Swiss CD-1®) Mice
  • AIDS Toxicity Report Number 2: NIEHS Technical Report on the Reproductive, Developmental, and General Toxicity Studies of 3'-Azido-3'-dioxythymidine (AZT), Trimethoprim (TMP)/ Sulfamethoxazole (SMX), and Folinic Acid Combinations Administered by Gavage to Swiss CD-1®) Mice
  • AIDS Toxicity Report Number 3: NIEHS Technical Report on the Reproductive, Developmental, and General Toxicity Studies of 3'-Azido-3'-dioxythymidine (AZT) and Isoniazid Combinations (CAS Nos. 30516-87-1 and 54-85-3) Administered by Gavage to Swiss CD-1®) Mice
  • AIDS Toxicity Report Number 4: NIEHS Technical Report on the Reproductive, Developmental, and General Toxicity Study of 3'-Azido-3'-deoxythymidine (AZT) and Rifabutin Combinations (CAS Nos. 30516-87-1 and 72559-06-9) Administered by Gavage to Swiss (CD-1®) Mice
  • AIDS Toxicity Report Number 5: NIEHS Technical Report on the Subchronic Toxicity Study of 3'-Azido-3'-dioxythymidine (AZT) and Pyrazinamide Combinations (CAS Nos. 30516-87-1 and 98-96-4) Administered by Gavage to B6C3F1 Mice
  • AIDS Toxicity Report Number 6: NIEHS Technical Report on the Subchronic Toxicity Study of 3'-Azido-3'-dioxythymidine (AZT) and Rifampin Combinations (CAS Nos. 30516-87-1 and 13292-46-1) Administered by Gavage to B6C3F1 Mice
  • AIDS Toxicity Report Number 7: NIEHS Technical Report on the Reproductive, Developmental, and General Toxicity Study of 3'-Azido-3'-deoxythymidine (AZT) and Pyrazinamide Combinations (CAS Nos. 30516-87-1 and 98-96-4) Administered by Gavage to Swiss CD-1® Mice
  • AIDS Toxicity Report Number 8: NIEHS Technical Report on the 13-Week Toxicity Study of 3'-Azido-3'-deoxythymidine (AZT) and Isoniazid Combinations (CAS Nos. 30516-87-1 and 54-85-3) Administered by Gavage to B6C3F1 Mice
  • AIDS Toxicity Report Number 9: NIEHS Technical Report on the Reproductive, Developmental, and General Toxicity Studies of 3'-Azido-3'-deoxythymidine (AZT) and Clarithromycin Combinations (CAS Nos. 30516-87-1 and 81103-11-9) Administered by Gavage to Swiss CD-1® Mice

AIDS Publication Abstracts:

To receive printed copies of these documents or publications, contact Central Data Management

Links to other AIDS Information Sites

NTP is located at the National Institute of Environmental Health Sciences, part of the National Institutes of Health.